Evidence map›Paper›PMID 28721524›Full record

ReviewCardiovascular drugs and therapy2017

Human iPSC-Derived Cardiomyocytes for Investigation of Disease Mechanisms and Therapeutic Strategies in Inherited Arrhythmia Syndromes: Strengths and Limitations.

Simona Casini, Arie O Verkerk, Carol Ann Remme

Open access · hybridAbstract readReview
In one paragraph

Review in Cardiovascular drugs and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Review
  3. Identification of Lauric Acid as a Potent Sodium Channel NaDrug design, development and therapy · 2025
    Article
  4. Article
  5. Review
  6. hiPSC-CM electrophysiology: impact of temporal changes and study parameters on experimental reproducibility.American journal of physiology. Heart and circulatory physiology · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Guidelines for assessment of cardiac electrophysiology and arrhythmias in small animals.American journal of physiology. Heart and circulatory physiology · 2022
    Review
  16. Article
  17. Acetylcholine Reduces IBiomedicines · 2022
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Simona CasiniDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, University of Amsterdam, Room K2-104-2, Meibergdreef 15, PO Box 22700, 1100 DE, Amsterdam, The Netherlands.
Arie O VerkerkDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, University of Amsterdam, Room K2-104-2, Meibergdreef 15, PO Box 22700, 1100 DE, Amsterdam, The Netherlands.
Carol Ann RemmeDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, University of Amsterdam, Room K2-104-2, Meibergdreef 15, PO Box 22700, 1100 DE, Amsterdam, The Netherlands. C.A.Remme@amc.uva.nl.ORCID http://orcid.org/0000-0003-0095-0084
Amsterdam UMC Location University of Amsterdam · NL

Funding

ZonMw 113303006ZonMw 91714371
6 · The paper itself

Abstract

During the last two decades, significant progress has been made in the identification of genetic defects underlying inherited arrhythmia syndromes, which has provided some clinical benefit through elucidation of gene-specific arrhythmia triggers and treatment. However, for most arrhythmia syndromes, clinical management is hindered by insufficient knowledge of the functional consequences of the mutation in question, the pro-arrhythmic mechanisms involved, and hence the most optimal treatment strategy. Moreover, disease expressivity and sensitivity to therapeutic interventions often varies between mutations and/or patients, underlining the need for more individualized strategies. The development of the induced pluripotent stem cell (iPSC) technology now provides the opportunity for generating iPSC-derived cardiomyocytes (CMs) from human material (hiPSC-CMs), enabling patient- and/or mutation-specific investigations. These hiPSC-CMs may furthermore be employed for identification and assessment of novel therapeutic strategies for arrhythmia syndromes. However, due to their relative immaturity, hiPSC-CMs also display a number of essential differences as compared to adult human CMs, and hence there are certain limitations in their use. We here review the electrophysiological characteristics of hiPSC-CMs, their use for investigating inherited arrhythmia syndromes, and their applicability for identification and assessment of (novel) anti-arrhythmic treatment strategies.

Indexed as

AnimalsAnti-Arrhythmia AgentsArrhythmias, CardiacCell DifferentiationHumansInduced Pluripotent Stem CellsMyocytes, CardiacSyndromeAnti-Arrhythmia AgentsArrhythmiasCardiomyocytesHumanInduced pluripotent stem cellsPharmacology

Identifiers

PMID28721524
PMCPMC5550530
OpenAlexW2737346820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.